20.02

2.25% -0.4131

Rigel Pharmaceuticals (RIGL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rigel Pharmaceuticals stock is traded at $20.02, with a volume of 28,171. It is down -2.25% in the last 24 hours and down -4.27% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Previous Close:

$20.43

Open:

$20.33

24h Volume:

28,171

Relative Volume:

0.11

Market Cap:

$364.94M

Revenue:

$116.88M

Net Income/Loss:

$-25.09M

P/E Ratio:

-142.98

EPS:

-0.14

Net Cash Flow:

$-20.74M

1W Performance:

+1.37%

1M Performance:

-4.27%

6M Performance:

+45.77%

1Y Performance:

+37.72%

1-Day Range:

$19.85

$20.57

1-Week Range:

$18.44

$20.88

52-Week Range:

$7.4843

$29.82

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name

Rigel Pharmaceuticals

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

650-624-1100

Address

611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA

Employee

164

Twitter

@rigelpharma

Next Earnings Date

2024-11-07

Latest SEC Filings

RIGL's Discussions on Twitter

Compare RIGL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RIGL Rigel Pharmaceuticals	19.97	364.94M	116.88M	-25.09M	-20.74M	-0.14
VRTX Vertex Pharmaceuticals Inc	498.93	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.13	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.71	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-23	Resumed	Piper Sandler	Neutral
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-23-22	Initiated	B. Riley Securities	Neutral
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight
Sep-26-19	Resumed	JP Morgan	Overweight
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight
Aug-27-18	Initiated	Citigroup	Buy
May-02-18	Reiterated	Cantor Fitzgerald	Overweight
Dec-21-17	Resumed	Piper Jaffray	Overweight
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight
Nov-06-17	Resumed	H.C. Wainwright	Buy
Mar-09-17	Reiterated	H.C. Wainwright	Buy
Aug-31-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Reiterated	Piper Jaffray	Overweight
Jul-13-16	Initiated	H.C. Wainwright	Buy
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight
Apr-08-13	Reiterated	Stifel	Buy
Nov-29-12	Initiated	UBS	Neutral
Nov-06-12	Reiterated	Oppenheimer	Outperform
Mar-26-12	Initiated	Canaccord Genuity	Hold
Dec-10-10	Downgrade	MP Advisors	Outperform → Market Perform

View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

Mar 12, 2025

Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com

Mar 12, 2025

Mar 11, 2025

Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha

Mar 11, 2025

Mar 10, 2025

Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada

Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia

Mar 10, 2025

Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com

Mar 10, 2025

Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN

Mar 10, 2025

Rigel Pharmaceuticals adds oncology expert to board - Investing.com India

Mar 10, 2025

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan

Mar 10, 2025

Mar 09, 2025

Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Mar 09, 2025

Mar 08, 2025

FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World

Mar 08, 2025

Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 08, 2025

Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN

Mar 08, 2025

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World

Mar 08, 2025

What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World

Mar 08, 2025

What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World

Mar 08, 2025

Mar 07, 2025

Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia

Mar 07, 2025

Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance

Mar 07, 2025

Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World

Mar 07, 2025

HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World

Mar 07, 2025

What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World

Mar 07, 2025

Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World

Mar 07, 2025

Mar 06, 2025

Rigel Pharmaceuticals price target raised to $55 from $49 at Citi - TipRanks

Mar 06, 2025

Mar 05, 2025

Rigel Pharmaceuticals Reports Record Sales and Strategic Growth - TipRanks

Mar 05, 2025

Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade - Nasdaq

Mar 05, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target By Investing.com - Investing.com South Africa

Mar 05, 2025

Rigel Pharmaceuticals stock holds Buy rating, $57 target - Investing.com India

Mar 05, 2025

B. Riley Raises Price Target on Rigel Pharmaceuticals to $24 From $20, Keeps Neutral Rating - Marketscreener.com

Mar 05, 2025

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Mar 05, 2025